Depression and cardiovascular risk-association among Beck Depression Inventory, PCSK9 levels and insulin resistance.
Beck Depression Inventory
Cardiovascular risk
Depression
Framingham risk score
Obesity
Proprotein Converatse Subtilisin/Kexin type 9
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
03 11 2020
03 11 2020
Historique:
received:
24
08
2020
accepted:
12
10
2020
entrez:
4
11
2020
pubmed:
5
11
2020
medline:
8
6
2021
Statut:
epublish
Résumé
Depression and cardiovascular disease (CVD) are among the most common causes of disability in high-income countries, depression being associated with a 30% increased risk of future CV events. Depression is twice as common in people with diabetes and is associated with a 60% rise in the incidence of type 2 diabetes, an independent CVD risk factor. Proprotein convertase subtilisin/kexin type 9 (PCSK9), a key regulator of low-density lipoprotein cholesterol, has been related to a large number of CV risk factors, including insulin resistance. Aim of this study was to investigate whether the presence of depression could affect PCSK9 levels in a population of obese subjects susceptible to depressive symptoms and how these changes may mediate a pre-diabetic risk. In 389 obese individuals, the Beck Depression Inventory (BDI-II) was significantly associated with PCSK9 levels. For every one-unit increment in BDI-II score, PCSK9 rose by 1.85 ng/mL. Depression was associated also with the HOMA-IR (homeostatic model assessment index of insulin resistance), 11% of this effect operating indirectly via PCSK9. This study indicates a possible mechanism linking depression and insulin resistance, a well-known CV risk factor, providing evidence for a significant role of PCSK9.
Sections du résumé
BACKGROUND
Depression and cardiovascular disease (CVD) are among the most common causes of disability in high-income countries, depression being associated with a 30% increased risk of future CV events. Depression is twice as common in people with diabetes and is associated with a 60% rise in the incidence of type 2 diabetes, an independent CVD risk factor. Proprotein convertase subtilisin/kexin type 9 (PCSK9), a key regulator of low-density lipoprotein cholesterol, has been related to a large number of CV risk factors, including insulin resistance. Aim of this study was to investigate whether the presence of depression could affect PCSK9 levels in a population of obese subjects susceptible to depressive symptoms and how these changes may mediate a pre-diabetic risk.
RESULTS
In 389 obese individuals, the Beck Depression Inventory (BDI-II) was significantly associated with PCSK9 levels. For every one-unit increment in BDI-II score, PCSK9 rose by 1.85 ng/mL. Depression was associated also with the HOMA-IR (homeostatic model assessment index of insulin resistance), 11% of this effect operating indirectly via PCSK9.
CONCLUSIONS
This study indicates a possible mechanism linking depression and insulin resistance, a well-known CV risk factor, providing evidence for a significant role of PCSK9.
Identifiants
pubmed: 33143700
doi: 10.1186/s12933-020-01158-6
pii: 10.1186/s12933-020-01158-6
pmc: PMC7641831
doi:
Substances chimiques
Biomarkers
0
PCSK9 protein, human
EC 3.4.21.-
Proprotein Convertase 9
EC 3.4.21.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
187Références
Diabetes Metab. 2020 Nov;46(6):480-487
pubmed: 32032671
J Psychiatry Neurosci. 2015 Jul;40(4):219-21
pubmed: 26107348
Atherosclerosis. 2016 Oct;253:214-224
pubmed: 27477186
Diabetes Metab Syndr. 2015 Jul-Sep;9(3):168-76
pubmed: 25943411
J Am Heart Assoc. 2017 May 3;6(5):
pubmed: 28468788
JAMA. 2018 Jul 24;320(4):350-358
pubmed: 30043065
JAMA. 2016 Jan 26;315(4):380-7
pubmed: 26813211
Eur J Prev Cardiol. 2019 Jun;26(9):930-949
pubmed: 30776916
Nutr Metab Cardiovasc Dis. 2019 Aug;29(8):815-821
pubmed: 31133497
JAMA Cardiol. 2018 Apr 1;3(4):280-287
pubmed: 29490333
Atherosclerosis. 2016 Sep;252:50-60
pubmed: 27501130
Nat Genet. 2009 Mar;41(3):334-41
pubmed: 19198609
N Engl J Med. 2015 Apr 2;372(14):1333-41
pubmed: 25830423
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jun 8;92:405-411
pubmed: 30779936
J Clin Endocrinol Metab. 2009 Jul;94(7):2537-43
pubmed: 19351729
Atheroscler Suppl. 2019 Mar;36:31-36
pubmed: 30876531
Arch Gen Psychiatry. 2010 Mar;67(3):220-9
pubmed: 20194822
N Engl J Med. 2017 Nov 16;377(20):1997
pubmed: 29141161
Eur Heart J. 2006 Dec;27(23):2763-74
pubmed: 17082208
Alcohol Clin Exp Res. 2019 Jun;43(6):1163-1169
pubmed: 30933362
Circ Genom Precis Med. 2018 Jul;11(7):e002162
pubmed: 29997226
Eur J Prev Cardiol. 2019 May;26(8):824-835
pubmed: 30739508
Int J Epidemiol. 2019 Jun 1;48(3):834-848
pubmed: 30423117
Int J Neuropsychopharmacol. 2018 Dec 1;21(12):1067-1075
pubmed: 29986042
Atherosclerosis. 2016 May;248:117-22
pubmed: 27015246
Lancet Diabetes Endocrinol. 2015 Jun;3(6):461-471
pubmed: 25995124
Diabetes Care. 2013 May;36(5):1088-94
pubmed: 23359362
JAMA. 1999 Nov 10;282(18):1737-44
pubmed: 10568646
Atherosclerosis. 2020 Jan;293:49-56
pubmed: 31835041
Eur J Prev Cardiol. 2019 Apr;26(6):578-588
pubmed: 30477320
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S454-66
pubmed: 22588766
Mediators Inflamm. 2020 Jun 4;2020:1348913
pubmed: 32565719
J Am Coll Cardiol. 2019 Apr 16;73(14):1827-1845
pubmed: 30975301
Eur Heart J. 2020 May 1;41(17):1687-1696
pubmed: 30698764
Circulation. 2004 Aug 17;110(7):803-9
pubmed: 15289378
Int J Neuropsychopharmacol. 2018 Dec 1;21(12):1076-1078
pubmed: 30329063
Circ Genom Precis Med. 2018 May;11(5):e001992
pubmed: 29748315
Diabetologia. 2013 Apr;56(4):686-95
pubmed: 23354123
Diabetes Care. 2008 Dec;31(12):2383-90
pubmed: 19033418
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):1179-1186
pubmed: 32673838
Diabetes Care. 2002 Jul;25(7):1135-41
pubmed: 12087010
N Engl J Med. 1999 Jan 7;340(1):14-22
pubmed: 9878640
Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):928-33
pubmed: 12552133
Biofactors. 2020 May;46(3):367-380
pubmed: 31999032
BMC Psychiatry. 2014 Dec 24;14:371
pubmed: 25540022
Diabetologia. 2020 Jul;63(7):1305-1311
pubmed: 32270255
Ann Behav Med. 2016 Feb;50(1):1-11
pubmed: 26318593
Mol Psychiatry. 2019 Jan;24(1):18-33
pubmed: 29453413
Circulation. 2016 Mar 29;133(13):1230-9
pubmed: 26896437
Eur Heart J. 2016 Feb 7;37(6):546-53
pubmed: 26655339
Cardiovasc Diabetol. 2019 Nov 9;18(1):149
pubmed: 31706300
J Biol Chem. 2006 Mar 10;281(10):6211-8
pubmed: 16407292
Cardiovasc Diabetol. 2019 Oct 31;18(1):144
pubmed: 31672148
BMC Public Health. 2014 Nov 04;14:1137
pubmed: 25371091
Front Psychiatry. 2019 Feb 14;10:57
pubmed: 30837902
Eur J Prev Cardiol. 2020 Mar;27(4):381-390
pubmed: 31349778
Circulation. 2008 Oct 21;118(17):1768-75
pubmed: 18824640
Eur Heart J. 2014 Jun 1;35(21):1365-72
pubmed: 24282187
Eur Heart J. 2016 Feb 7;37(6):554-60
pubmed: 26508163
Psychol Sci. 2013 Oct;24(10):1918-27
pubmed: 23955356
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
Lancet. 2004 Sep 11-17;364(9438):937-52
pubmed: 15364185
Cardiovasc Diabetol. 2020 Mar 13;19(1):33
pubmed: 32169071
Nutr Metab Cardiovasc Dis. 2020 Nov 27;30(12):2372-2378
pubmed: 33028503
N Engl J Med. ;377(20):1996-7
pubmed: 29143516
Eur J Prev Cardiol. 2020 May;27(8):800-807
pubmed: 31529992
Circ Genom Precis Med. 2019 Jan;12(1):e002196
pubmed: 30645167
Front Neurosci. 2020 Jun 12;14:609
pubmed: 32595449